Literature DB >> 15968390

Angiotensin II enhances thrombosis development in renovascular hypertensive rats.

Andrzej Mogielnicki1, Ewa Chabielska, Robert Pawlak, Janusz Szemraj, Wlodzimierz Buczko.   

Abstract

There is an increased number of in vitro evidence that angiotensin II (Ang II) may promote thrombosis. However there are no in vivo experiments exploring the effect of Ang II on thrombus formation. In the present study we have investigated the influence of Ang II on venous thrombosis in renovascular hypertensive rats. Furthermore, we examined the role of AT(1) receptor and Ang II metabolites: angiotensin III (Ang III) and angiotensin IV (Ang IV) in the mechanisms of Ang II action. The contribution of coagulation and fibrinolytic systems in the mode of Ang II action was also determined. Venous thrombosis was induced by ligation of vena cava. Ang II infused into rats developing venous thrombosis caused dose-dependent increase in thrombus weight, which was partially reversed by losartan, selective AT(1) antagonist. Ang III did not influence the thrombus formation in hypertensive rats, while Ang IV caused a marked increase in thrombus weight only in one of the used doses. Our study shows that Ang II via AT(1) receptor enhances thrombosis development. The prothrombotic effect of Ang II may partially depend on enhanced leukocytes adhesion to endothelial cells accompanied by accelerated fibrin formation and increased plasma level of PAI-1. Moreover, Ang II action is partially mediated by one of its metabolites - Ang IV.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15968390     DOI: 10.1160/TH04-10-0701

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  16 in total

1.  Angiotensin II-mediated microvascular thrombosis.

Authors:  Elena Y Senchenkova; Janice Russell; Lidiana D Almeida-Paula; Joseph W Harding; D Neil Granger
Journal:  Hypertension       Date:  2010-10-25       Impact factor: 10.190

2.  Elevated blood pressure aggravates intracerebral hemorrhage-induced brain injury.

Authors:  Yan-Hua Sang; Huan-Xing Su; Wu-Tian Wu; Kwok-Fai So; Raymond Tak-Fai Cheung
Journal:  J Neurotrauma       Date:  2011-10-11       Impact factor: 5.269

Review 3.  Stabilization of high-risk plaques.

Authors:  Kohei Takata; Satoshi Imaizumi; Bo Zhang; Shin-Ichiro Miura; Keijiro Saku
Journal:  Cardiovasc Diagn Ther       Date:  2016-08

Review 4.  Acute hypertensive response in patients with intracerebral hemorrhage pathophysiology and treatment.

Authors:  Adnan I Qureshi; Mushtaq H Qureshi
Journal:  J Cereb Blood Flow Metab       Date:  2017-08-16       Impact factor: 6.200

5.  Role of T lymphocytes in angiotensin II-mediated microvascular thrombosis.

Authors:  Elena Y Senchenkova; Janice Russell; Elvira Kurmaeva; Dmitry Ostanin; D Neil Granger
Journal:  Hypertension       Date:  2011-09-12       Impact factor: 10.190

Review 6.  Interactions of renin-angiotensin system and COVID-19: the importance of daily rhythms in ACE2, ADAM17 and TMPRSS2 expression.

Authors:  J Zlacká; K Stebelová; M Zeman; I Herichová
Journal:  Physiol Res       Date:  2021-12-16       Impact factor: 1.881

7.  Roles of Coagulation and fibrinolysis in angiotensin II-enhanced microvascular thrombosis.

Authors:  Elena Y Senchenkova; Janice Russell; Charles T Esmon; D Neil Granger
Journal:  Microcirculation       Date:  2014-07       Impact factor: 2.628

8.  1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway.

Authors:  S Chlopicki; J Swies; A Mogielnicki; W Buczko; M Bartus; M Lomnicka; J Adamus; J Gebicki
Journal:  Br J Pharmacol       Date:  2007-07-16       Impact factor: 8.739

9.  Protective Role of the ACE2/Ang-(1-9) Axis in Cardiovascular Remodeling.

Authors:  María Paz Ocaranza; Jorge E Jalil
Journal:  Int J Hypertens       Date:  2012-01-19       Impact factor: 2.420

Review 10.  Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.

Authors:  Satoshi Gando; Takeshi Wada
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.